Education
About Us
Working with TipRanks
Follow Us
Puretech Health Plc (PRTC)
:PRTC
PRTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.10 - $33.51
Previous CloseN/A
Volume2.03K
Average Volume (3M)2.55K
Market Cap
$436.76M
Enterprise Value$448.27M
Total Cash (Recent Filing)$7.17M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Apr 24, 2025EPS Estimate
-2.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.02
Shares Outstanding24,018,946
10 Day Avg. Volume4,049
30 Day Avg. Volume2,551
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)533.91
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-279.65
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$46.00Price Target Upside141.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Bulls Say, Bears Say
Bulls Say
Business ModelThe hybrid business model of Puretech Health Plc, combining drug development and company incubation, offers multiple ways to succeed over the long term.
Drug DevelopmentLYT-100 is seen as the most promising wholly-owned program within Puretech Health Plc, demonstrating potential as a real drug in the high unmet need and large market opportunity in IPF.
Earnings PotentialPRTC stands to benefit from potential milestones (up to $400M+) and royalties on sales >$2B.
Bears Say
Product EfficacyLYT-100 550mg shows more tolerability than pirfenidone, though with modestly lower efficacy, which may limit its appeal.
Stock LiquidityPRTC stock continues to be dislocated due to investor base turnover and low liquidity for the ADRs.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
1.36% Other Institutional Investors
98.64% Public Companies and
Individual Investors
PRTC FAQ
What was Puretech Health Plc’s price range in the past 12 months?
Puretech Health Plc lowest stock price was $16.10 and its highest was $33.51 in the past 12 months.
What is Puretech Health Plc’s market cap?
Puretech Health Plc’s market cap is $436.76M.
When is Puretech Health Plc’s upcoming earnings report date?
Puretech Health Plc’s upcoming earnings report date is Apr 24, 2025 which is in 19 days.
How were Puretech Health Plc’s earnings last quarter?
Puretech Health Plc released its earnings results on Aug 28, 2024. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$3.03 by $1.53.
Is Puretech Health Plc overvalued?
According to Wall Street analysts Puretech Health Plc’s price is currently Undervalued.
Does Puretech Health Plc pay dividends?
Puretech Health Plc does not currently pay dividends.
What is Puretech Health Plc’s EPS estimate?
Puretech Health Plc’s EPS estimate is -2.83.
How many shares outstanding does Puretech Health Plc have?
Puretech Health Plc has 24,018,946 shares outstanding.
What happened to Puretech Health Plc’s price movement after its last earnings report?
Puretech Health Plc reported an EPS of -$1.5 in its last earnings report, beating expectations of -$3.03. Following the earnings report the stock price went down -6%.
Which hedge fund is a major shareholder of Puretech Health Plc?
Currently, no hedge funds are holding shares in PRTC
---
PureTech Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.00 (141.34% Upside)
$46.00 (141.34% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.80%
12-Months-Change
Fundamentals
Return on Equity
-19.80%
Trailing 12-Months
Asset Growth
-16.38%
Trailing 12-Months
Company Description
Puretech Health Plc
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
---
PRTC Stock 12 Month Forecast
Average Price Target
$46.00
▲(141.34% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Neurocrine
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering PRTC
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-12.07%
reiterated a buy rating 4 months ago
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -12.07% per trade.
---